Table 5.
Disease activity during follow-up.
| Anti-Ku (n=17) |
DM (n=202) |
AS (n=168) |
IBM (n=387) |
IMNM (n=169) |
Anti-U1RNP (n=20) |
Anti-PM/SCl (n=47) |
Total (n=1010) |
|
|---|---|---|---|---|---|---|---|---|
| Mean hip flexor strength | 7.5 (3.3) | 8.7 (1.9)* | 9.1 (1.4)*** | 7.5 (2.5) | 6.4 (2.9) | 8.8 (1.9) | 9.2 (1.5)** | 8.0 (2.4) |
| Hip flexors strength at last visit | 9.2 (1.0) | 9.0 (2.0) | 9.3 (1.4) | 7.3 (2.7)* | 6.7 (3.6)* | 9.8 (0.4) | 9.1 (1.8) | 8.1 (2.7) |
| Mean arm abductor strength | 8.4 (2.2) | 9.0 (1.6) | 9.4 (1.0)*** | 9.0 (1.8) | 8.4 (2.0) | 9.4 (0.7) | 8.6 (2.4) | 9.0 (1.7) |
| Arm abductors strength at last visit | 9.2 (1.7) | 9.2 (1.9) | 9.5 (1.1) | 8.8 (2.2) | 8.5 (2.5) | 9.7 (0.6) | 8.6 (2.5) | 9.0 (2.1) |
| Median CK | 493 (207–872) | 121 (70–328)* | 282 (108–1020) | 426 (218–703) | 1387 (501–2874)** | 237 (135–696) | 138 (78–509) | 362 (136–868) |
| Maximum CK | 567 (328–1361) | 806 (139–3513) | 1439 (330–6000) | 543 (270–977) | 5372 (2274–10000)*** | 760 (507–4166) | 1149 (247–3000) | 948 (314–3600) |
| Mean aldolase | 9.5 (5.7) | 9.6 (7.4) | 45.7 (296.0) | 11.6 (9.5) | 34.0 (47.0) | 20.1 (19.0) | 13.8 (11.9) | 21.8 (133.5) |
| Maximum aldolase | 14.5 (12.5) | 13.0 (14.7) | 131.0 (1177.7) | 14.3 (30.8) | 55.8 (70.3)* | 36.1 (41.0) | 23.3 (22.2) | 44.8 (524.8) |
*
p < 0.05,
**
p < 0.01,
***
p < 0.001.
Abbreviations: DM = dermatomyositis; AS = antisynthetase syndrome; IBM = inclusion body myositis; IMNM = immune-mediated necrotizing myopathy; anti-U1RNP = anti-U1 ribonucleoprotein; anti-PM/SCl = anti-PM/SCl complex;; CK = creatine kinase
Strength and aldolase values expressed as mean (SD) and CK as median (Q1–Q3). Bivariate comparisons made using Student’s t-test for strength and Wilcoxon rank-sum test for CK. Each of the clinical groups was compared to the sample of anti-Ku-positive patients